Drugs / PfSPZ-LARC2 Vaccine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06862453 | Mar → Sep 2026 overdue | Plasmodium falciparum malaria | Sanaria Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06735209 | Jul 2025 → Feb 2027 expected | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06652737 | Mar 2025 → Feb 2026 | Plasmodium falciparum malaria | Sanaria Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07675785 | Jul 2026 → Jul 2028 expected | Plasmodium falciparum malaria | Sanaria Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07385287 | May 2026 → Feb 2027 expected | Plasmodium falciparum malaria | Sanaria Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-06-03 | Sanaria Inc. | Results Sanaria Reports Positive Initial Safety Results for Groundbreaking PfSPZ-LARC2 Malaria Vaccine sanaria.com ↗
Crucially, the initial data in adults confirmed the vaccine was safe, fully attenuated, and caused no malaria infections. |
| 2025-02-12 | Sanaria Inc. | Results A Single-Dose Breakthrough: PfSPZ-LARC Vaccines Offer Transformative Protection Against Malaria sanaria.com ↗
Recent data suggest that PfSPZ-LARC2’s single-dose approach could redefine malaria prevention and elimination efforts globally and have put the WHO goal within sight. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-03 | Sanaria Inc. | Sanaria Reports Positive Initial Safety Results for Groundbreaking PfSPZ-LARC2 Malaria Vaccine sanaria.com ↗ |
| 2025-02-12 | Sanaria Inc. | A Single-Dose Breakthrough: PfSPZ-LARC Vaccines Offer Transformative Protection Against Malaria sanaria.com ↗ |
| 2024-04-01 | Sanaria Inc. | Novel vaccine, PfSPZ-LARC2 Vaccine, to prevent malaria infection developed by Seattle Children’s Research Institute and Sanaria ready for human testing sanaria.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PfSPZ-LARC2 Vaccine | “PfSPZ-LARC2 Vaccine is composed of aseptic, purified, vialed, cryopreserved, genetically altered PfNF54 sporozoites (SPZ).” NCT07385287 ↗4“PfSPZ-LARC2 Vaccine is a late-arresting, replication-competent whole Plasmodium falciparum sporozoite product.” NCT06735209 ↗ |
| Known as | Sanaria PfSPZ-LARC2 Vaccine | “This is a phase 2 clinical trial of a Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) vaccine (Sanaria® PfSPZ-LARC2 Vaccine)...” NCT07385287 ↗1“Sanaria® PfSPZ-LARC2 Vaccine” NCT06652737 ↗ |
| Modality | Vaccine | “Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) malaria vaccine” NCT06652737 ↗ |
| Route | Intravenous | “administered to healthy, malaria-exposed adults and children by direct venous inoculation (DVI)” NCT06652737 ↗ |